All In Biotech

Free tool

FAERS Monitor: Evista

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020815 or its brand name (Evista, Raloxifene Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

14,534

Serious

8,238

57% of reports

Hospitalization

3,468

Death reported

560

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea777
  • fall772
  • drug ineffective751
  • pain in extremity717
  • pain686
  • arthralgia637
  • dizziness615
  • muscle spasms588
  • fatigue565
  • headache557
  • body height decreased532
  • back pain470
  • diarrhoea468
  • bone density decreased456
  • dyspnoea453

Reports by year received

View as table
YearReports
20041,125
2005990
2006855
2007715
2008758
2009743
2010793
2011621
2012757
2013530
2014554
20153,688
2016471
2017429
2018325
2019291
2020205
2021165
2022145
2023113
202499
202596
202665

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,625 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
body height decreasedSignal53275.769.537,220
bone density decreasedSignal45621.419.58,712
muscle spasmsSignal5884.64.31,689
pain in extremitySignal7173.53.31,311
fallSignal7723.43.11,296
back painSignal4702.92.7602
arthralgiaSignal6372.22.1433
dizziness6151.81.7217
pain6861.61.5165
nausea7771.41.3100
headache5571.31.236
dyspnoea4531.21.110
fatigue5651.11.01
diarrhoea4681.01.01
drug ineffective7510.80.830

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.